Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioSurface Technology Inc., Genzyme deal

As part of the transaction, GENZ's shareholders also approved the issuance of a new class of common stock (GENZL) that will

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE